JP2021511031A - 増強した生物学的封じ込め材料および増強した生物学的封じ込めエンクロージャー - Google Patents
増強した生物学的封じ込め材料および増強した生物学的封じ込めエンクロージャー Download PDFInfo
- Publication number
- JP2021511031A JP2021511031A JP2020539029A JP2020539029A JP2021511031A JP 2021511031 A JP2021511031 A JP 2021511031A JP 2020539029 A JP2020539029 A JP 2020539029A JP 2020539029 A JP2020539029 A JP 2020539029A JP 2021511031 A JP2021511031 A JP 2021511031A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- copolymer
- biological
- enhancer
- biological containment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000463 material Substances 0.000 title description 17
- 239000000203 mixture Substances 0.000 claims abstract description 115
- 229920001577 copolymer Polymers 0.000 claims abstract description 39
- 239000003623 enhancer Substances 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 20
- YZRXGCVCALWUON-UHFFFAOYSA-N decanedioic acid ethyl carbamate propane-1,2,3-triol Chemical compound CCOC(N)=O.OCC(O)CO.OC(=O)CCCCCCCCC(O)=O YZRXGCVCALWUON-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000758 substrate Substances 0.000 claims abstract description 11
- LKFHUFAEFBRVQX-UHFFFAOYSA-N decanedioic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)CCCCCCCCC(O)=O LKFHUFAEFBRVQX-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000008901 benefit Effects 0.000 claims abstract description 9
- 230000003014 reinforcing effect Effects 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 238000005728 strengthening Methods 0.000 claims abstract description 4
- 238000003860 storage Methods 0.000 claims description 33
- 235000015097 nutrients Nutrition 0.000 claims description 17
- 239000000835 fiber Substances 0.000 claims description 12
- 239000002516 radical scavenger Substances 0.000 claims description 12
- 238000002161 passivation Methods 0.000 claims description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 9
- 102000001554 Hemoglobins Human genes 0.000 claims description 8
- 108010054147 Hemoglobins Proteins 0.000 claims description 8
- 239000003146 anticoagulant agent Substances 0.000 claims description 7
- 229940127219 anticoagulant drug Drugs 0.000 claims description 7
- 239000002907 paramagnetic material Substances 0.000 claims description 7
- 239000003053 toxin Substances 0.000 claims description 7
- 239000004800 polyvinyl chloride Substances 0.000 claims description 6
- 231100000765 toxin Toxicity 0.000 claims description 6
- 108700012359 toxins Proteins 0.000 claims description 6
- 235000012438 extruded product Nutrition 0.000 claims description 5
- 239000004014 plasticizer Substances 0.000 claims description 5
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 3
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 claims 8
- 239000001272 nitrous oxide Substances 0.000 claims 4
- 238000004321 preservation Methods 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000010586 diagram Methods 0.000 abstract 1
- 239000010408 film Substances 0.000 description 61
- 238000000576 coating method Methods 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 40
- 229920000642 polymer Polymers 0.000 description 40
- 239000011248 coating agent Substances 0.000 description 33
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 24
- 239000000126 substance Substances 0.000 description 18
- 239000010410 layer Substances 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 229920005989 resin Polymers 0.000 description 15
- 239000011347 resin Substances 0.000 description 15
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 230000004224 protection Effects 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 235000016709 nutrition Nutrition 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 8
- 239000002131 composite material Substances 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000004035 construction material Substances 0.000 description 7
- 230000035764 nutrition Effects 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 239000006227 byproduct Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 5
- 229930024421 Adenine Natural products 0.000 description 5
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229960000643 adenine Drugs 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 239000007888 film coating Substances 0.000 description 4
- 238000009501 film coating Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- -1 polyethylene terephthalate Polymers 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920006254 polymer film Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012876 topography Methods 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000004103 aerobic respiration Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000012237 artificial material Substances 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229960000182 blood factors Drugs 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000013590 bulk material Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002032 lab-on-a-chip Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000002952 polymeric resin Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000004381 surface treatment Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000004343 Calcium peroxide Substances 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 108010080864 Lactate Dehydrogenases Proteins 0.000 description 1
- 102000000428 Lactate Dehydrogenases Human genes 0.000 description 1
- 239000002879 Lewis base Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N Norphytane Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000004099 anaerobic respiration Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003373 anti-fouling effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 229920006167 biodegradable resin Polymers 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000002599 biostatic effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- LHJQIRIGXXHNLA-UHFFFAOYSA-N calcium peroxide Chemical compound [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 description 1
- 235000019402 calcium peroxide Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000000805 composite resin Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005685 electric field effect Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000007527 lewis bases Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 230000001453 nonthrombogenic effect Effects 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000005498 phthalate group Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000006068 polycondensation reaction Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011342 resin composition Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002520 smart material Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940045872 sodium percarbonate Drugs 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000002407 tissue scaffold Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/20—Material Coatings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/14—Bags
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/26—Constructional details, e.g. recesses, hinges flexible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/28—Constructional details, e.g. recesses, hinges disposable or single use
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/52—Mobile; Means for transporting the apparatus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/46—Means for regulation, monitoring, measurement or control, e.g. flow regulation of cellular or enzymatic activity or functionality, e.g. cell viability
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Sustainable Development (AREA)
- Clinical Laboratory Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
[0001]本出願は、その全体が参照により組み入れられる2018年1月17日付けで出願された米国仮出願第62/618,419号の優先権と利益を主張する。
[0002]本出願は、生物学的封じ込めおよび細胞培養に向けられる。より具体的には、本出願は、増強した生物学的封じ込め材料、増強した生物学的封じ込めエンクロージャー、およびそれを作製および使用するための方法に向けられる。
[0013]本発明の様々な特徴および利点は、一例として発明の原理を例示する添付の図面と併せて、以下のより詳細な説明から明らかであると予想される。
[0043]コーティングおよび表面処理は、非生体適合性表面を生体適合性表面に変化させる簡単な方法である。コーティングは、培養環境において、複数の必須の成分を送達できる媒体とみなされる場合もあり、またはバリアのパシベーションを介して、非生体適合性表面を生体適合性表面に変化させることもできる。
[0047]使い捨ての生物学的封じ込め産業における汎用のフィルムストックには、生物学的封じ込め用途のためのカスタム設計された材料がなかった。医療用デバイス分野におけるほとんどのものと同様に、これらの構築材料は流用されたものであり、流用されたものであるために細胞適合性の問題と取り組まなければならない。
12 構造組成物
14 強化組成物
16 外面
18 内面
32 内部フィルム層
34 機能的な改変
36 進路
Claims (27)
- 構造組成物;および
該構造組成物に付随する強化組成物
を含む容器構造を含む生物学的封じ込め容器であって、該強化組成物は、ポリ(グリセロールセバシン酸)およびポリ(グリセロールセバシン酸ウレタン)からなる群から選択されるコポリマーを含む、上記生物学的封じ込め容器。 - 前記構造組成物が、ポリ塩化ビニルを含む、請求項1に記載の生物学的封じ込め容器。
- 前記強化組成物が、前記容器構造の封じ込め側の前記構造組成物の表面上に配置されている、請求項1に記載の生物学的封じ込め容器。
- 前記容器構造の封じ込め側の前記強化組成物の表面上に、内部フィルム層をさらに含む、請求項3に記載の生物学的封じ込め容器。
- 前記強化組成物が、前記構造組成物と混合された可塑剤である、請求項1に記載の生物学的封じ込め容器。
- 前記コポリマーが、ポリ(グリセロールセバシン酸)である、請求項1に記載の生物学的封じ込め容器。
- 前記コポリマーが、ポリ(グリセロールセバシン酸ウレタン)である、請求項1に記載の生物学的封じ込め容器。
- 前記強化組成物が、前記コポリマーに付随する増強剤をさらに含み、前記強化組成物が前記構造組成物に対して、前記増強剤が、前記生物学的封じ込め容器に封じ込められた生物学的細胞に利益をもたらすように配置されている、請求項1に記載の生物学的封じ込め容器。
- 前記増強剤が、前記コポリマーと物理的に混合されている、請求項8に記載の生物学的封じ込め容器。
- 前記増強剤が、前記コポリマーに化学的に結合している、請求項8に記載の生物学的封じ込め容器。
- 前記増強剤が、細胞の栄養素、2−3−ジホスホグリセリン酸スカベンジャー、亜酸化窒素のヘモグロビン捕捉から保護する組成物、毒素に対する親和性組成物、繊維押出し物、常磁性材料、乳酸スカベンジャー、細胞保存組成物、抗凝血組成物、衛生組成物、表面パシベーション組成物、およびそれらの組合せからなる群から選択される、請求項8に記載の生物学的封じ込め容器。
- 生物学的細胞を封じ込める方法であって、
請求項1に記載の増強された生物学的封じ込め容器内に生物学的細胞を入れること;および
予め決定された条件下で、該増強された生物学的封じ込め容器中に該生物学的細胞を貯蔵すること
を含む、上記方法。 - 前記コポリマーが、ポリ(グリセロールセバシン酸)である、請求項12に記載の方法。
- 前記コポリマーが、ポリ(グリセロールセバシン酸ウレタン)である、請求項12に記載の方法。
- 前記強化組成物が、前記コポリマーに付随する増強剤をさらに含み、前記強化組成物が前記構造組成物に対して、前記増強剤が、前記生物学的封じ込め容器に封じ込められた前記生物学的細胞に利益をもたらすように配置されている、請求項12に記載の方法。
- 前記増強剤が、前記コポリマーと物理的に混合されている、請求項15に記載の方法。
- 前記増強剤が、前記コポリマーに化学的に結合している、請求項15に記載の方法。
- 前記増強剤が、細胞の栄養素、2−3−ジホスホグリセリン酸スカベンジャー、亜酸化窒素のヘモグロビン捕捉から保護する組成物、毒素に対する親和性組成物、繊維押出し物、常磁性材料、乳酸スカベンジャー、細胞保存組成物、抗凝血組成物、衛生組成物、表面パシベーション組成物、およびそれらの組合せからなる群から選択される、請求項15に記載の方法。
- ポリ(グリセロールセバシン酸)およびポリ(グリセロールセバシン酸ウレタン)からなる群から選択されるコポリマー;並びに
該コポリマーに付随する増強剤
を含む組成物。 - 前記増強剤が、生物学的細胞に少なくとも1つの生物学的な利益を提供する、請求項19に記載の組成物。
- 前記コポリマーが、ポリ(グリセロールセバシン酸)である、請求項19に記載の組成物。
- 前記コポリマーが、ポリ(グリセロールセバシン酸ウレタン)である、請求項19に記載の組成物。
- 前記増強剤が、前記コポリマーと物理的に混合されている、請求項19に記載の組成物。
- 前記増強剤が、前記コポリマーに化学的に結合している、請求項19に記載の組成物。
- 前記増強剤が、細胞の栄養素、2−3−ジホスホグリセリン酸スカベンジャー、亜酸化窒素のヘモグロビン捕捉から保護する組成物、毒素に対する親和性組成物、繊維押出し物、常磁性材料、乳酸スカベンジャー、細胞保存組成物、抗凝血組成物、衛生組成物、表面パシベーション組成物、およびそれらの組合せからなる群から選択される、請求項19に記載の組成物。
- 基板;および
該基板の表面をコーティングすること強化組成物
を含む増強された基板であって、該強化組成物は、ポリ(グリセロールセバシン酸)およびポリ(グリセロールセバシン酸ウレタン)からなる群から選択されるコポリマーを含む、上記基板。 - 前記強化組成物が、細胞の栄養素、2−3−ジホスホグリセリン酸スカベンジャー、亜酸化窒素のヘモグロビン捕捉から保護する組成物、毒素に対する親和性組成物、繊維押出し物、常磁性材料、乳酸スカベンジャー、細胞保存組成物、抗凝血組成物、衛生組成物、表面パシベーション組成物、およびそれらの組合せからなる群から選択される増強剤をさらに含む、請求項26に記載の増強された基板。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862618419P | 2018-01-17 | 2018-01-17 | |
US62/618,419 | 2018-01-17 | ||
PCT/US2019/013997 WO2019143807A1 (en) | 2018-01-17 | 2019-01-17 | Augmented biocontainment materials and augmented biocontainment enclosures |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021511031A true JP2021511031A (ja) | 2021-05-06 |
Family
ID=65324632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020539029A Pending JP2021511031A (ja) | 2018-01-17 | 2019-01-17 | 増強した生物学的封じ込め材料および増強した生物学的封じ込めエンクロージャー |
Country Status (8)
Country | Link |
---|---|
US (2) | US11208627B2 (ja) |
EP (1) | EP3740528A1 (ja) |
JP (1) | JP2021511031A (ja) |
KR (1) | KR20200110657A (ja) |
CN (1) | CN111615531A (ja) |
CA (1) | CA3088947A1 (ja) |
IL (1) | IL275827A (ja) |
WO (1) | WO2019143807A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11939444B2 (en) * | 2020-04-09 | 2024-03-26 | The Secant Group, Llc | Modified polymer film surfaces for single-use bioreactor bags and biocontainment and methods of forming same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004094586A2 (en) * | 2003-04-18 | 2004-11-04 | Carnegie Mellon University | Three-dimentional, flexible cell growth substrate and related methods |
JP2009525144A (ja) * | 2006-02-03 | 2009-07-09 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | ポリマー薄膜上の設計された細胞増殖およびその生物工学的応用 |
US20130231412A1 (en) * | 2011-08-26 | 2013-09-05 | Robert S. Langer | Urethane-crosslinked biodegradable elastomers |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7722894B2 (en) | 2001-10-22 | 2010-05-25 | Massachusetts Institute Of Technology | Biodegradable polymer |
US8980300B2 (en) * | 2004-08-05 | 2015-03-17 | Advanced Cardiovascular Systems, Inc. | Plasticizers for coating compositions |
US11730676B2 (en) * | 2012-08-22 | 2023-08-22 | Hemerus Medical, Llc | Blood storage container containing aqueous composition for the storage of red blood cells |
US9533072B2 (en) | 2012-10-08 | 2017-01-03 | Cormatrix Cardiovascular, Inc. | Reinforced vascular prostheses |
JP6538087B2 (ja) | 2014-05-30 | 2019-07-03 | ザ・セカント・グループ・エルエルシー | ポリマー材料の水媒介製造 |
US20160143738A1 (en) * | 2014-11-26 | 2016-05-26 | Cormatrix Cardiovascular, Inc. | Biological Constructs for Treating Damaged Organs and Tissue |
US11371003B2 (en) | 2016-02-05 | 2022-06-28 | Wisconsin Alumni Research Foundation | Photoreceptor scaffold for in vitro modeling and transplantation therapy |
-
2019
- 2019-01-17 WO PCT/US2019/013997 patent/WO2019143807A1/en unknown
- 2019-01-17 KR KR1020207021606A patent/KR20200110657A/ko not_active Application Discontinuation
- 2019-01-17 CN CN201980008907.3A patent/CN111615531A/zh active Pending
- 2019-01-17 US US16/250,457 patent/US11208627B2/en active Active
- 2019-01-17 EP EP19703886.2A patent/EP3740528A1/en active Pending
- 2019-01-17 CA CA3088947A patent/CA3088947A1/en active Pending
- 2019-01-17 JP JP2020539029A patent/JP2021511031A/ja active Pending
-
2020
- 2020-07-02 IL IL275827A patent/IL275827A/en unknown
-
2021
- 2021-11-30 US US17/538,241 patent/US20220090006A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004094586A2 (en) * | 2003-04-18 | 2004-11-04 | Carnegie Mellon University | Three-dimentional, flexible cell growth substrate and related methods |
JP2009525144A (ja) * | 2006-02-03 | 2009-07-09 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | ポリマー薄膜上の設計された細胞増殖およびその生物工学的応用 |
US20130231412A1 (en) * | 2011-08-26 | 2013-09-05 | Robert S. Langer | Urethane-crosslinked biodegradable elastomers |
Also Published As
Publication number | Publication date |
---|---|
EP3740528A1 (en) | 2020-11-25 |
CN111615531A (zh) | 2020-09-01 |
IL275827A (en) | 2020-08-31 |
US20220090006A1 (en) | 2022-03-24 |
US20190218507A1 (en) | 2019-07-18 |
US11208627B2 (en) | 2021-12-28 |
KR20200110657A (ko) | 2020-09-24 |
WO2019143807A1 (en) | 2019-07-25 |
CA3088947A1 (en) | 2019-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vishwakarma et al. | Engineering immunomodulatory biomaterials to tune the inflammatory response | |
Smith et al. | Harnessing macrophage plasticity for tissue regeneration | |
Simmchen et al. | Progress in the removal of di-[2-ethylhexyl]-phthalate as plasticizer in blood bags | |
Angelova et al. | Rationalizing the design of polymeric biomaterials | |
CN105307695B (zh) | 具有提高稳定性的抗血栓/杀菌s‑亚硝基‑n‑乙酰基青霉胺(snap)掺杂氧化氮释放聚合物 | |
AU2014363694B2 (en) | A chamber for encapsulating secreting cells | |
Douglass et al. | Bio-inspired hemocompatible surface modifications for biomedical applications | |
Mackie et al. | Clinical potential of immobilized liquid interfaces: perspectives on biological interactions | |
CN104927348A (zh) | 抗菌抗凝血高分子材料及其制备方法和应用 | |
Luneva et al. | Bilayer hydrogels for wound dressing and tissue engineering | |
JP2023516747A (ja) | 水和物品用包装および関連方法 | |
US20220090006A1 (en) | Augmented biocontainment materials and augmented biocontainment enclosures | |
CN201669064U (zh) | 抗凝血复合超滤膜 | |
Feng et al. | Surface modification of biomaterials by photochemical immobilization and photograft polymerization to improve hemocompatibility | |
Trombino et al. | Polymeric based hydrogel membranes for biomedical applications | |
Woźniak-Budych | Polymeric membranes for biomedical applications | |
CN102477172B (zh) | 壳聚糖-肝素纳米颗粒以及用该纳米颗粒处理的去细胞基质的生物材料 | |
Hu et al. | Hybrid polydimethylsiloxane bioscaffold-intravascular catheter for cellular therapies | |
US10350328B2 (en) | Surface modification of medical or veterinary devices | |
Farrugia et al. | Perspectives on the use of biomaterials to store platelets for transfusion | |
Liu et al. | Application of nanomedicine in wound healing | |
Chen et al. | Immune evaluation of granulocyte-macrophage colony stimulating factor loaded hierarchically 3D nanofiber scaffolds in a humanized mice model | |
Wu et al. | In vivo assessment of dual-function submicron textured nitric oxide releasing catheters in a 7-day rabbit model | |
Fijalkowski et al. | Development and characterization of native and citric acid-modified cellulose's drug-delivery system for bacterial biofilm eradication | |
Biscegli et al. | The Extracorporeal Circulation Circuit Versus Bioengineering Biomaterials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220107 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230111 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230410 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230728 |